Vascular morphogenesis in the primate ovary

被引:71
作者
Fraser H.M. [1 ,3 ,4 ]
Duncan W.C. [2 ]
机构
[1] MRC Human Reproductive Sciences Unit, Centre for Reproductive Biology, Edinburgh
[2] Department of Reproductive and Developmental Sciences, Centre for Reproductive Biology, Edinburgh
[3] MRC Human Reproductive Sciences Unit, Centre for Reproductive Biology, University of Edinburgh Chancellor's Building, Edinburgh
[4] MRC Human Reproductive Sciences Unit, Centre for Reproductive Biology, University of Edinburgh Chancellor's Building, Edinburgh, EH16 4SB
关键词
Corpus luteum; Follicle; Inhibition of angiogenesis; Ovary; VEGF antagonists;
D O I
10.1007/s10456-005-9004-y
中图分类号
学科分类号
摘要
Ovarian function is dependent on intense cyclical vascular morphogenesis and regression. The molecular and cellular pathways involved in the generation of new capillary networks in the ovary are now being elucidated. Focussing on the marmoset, the course of angiogenesis at different stages of follicular maturation and in the corpus luteum throughout the cycle and in early pregnancy have been quantified and major progress has been made in the evaluation of the role of vascular endothelial growth factor (VEGF). To study the physiological role of VEGF in follicular and luteal angiogenesis in detail, VEGF was inhibited during defined stages of the cycle in vivo. VEGF antagonist administered throughout the follicular phase of the cycle resulted in a marked decrease in endothelial cell proliferation in developing antral follicles, accompanied by a decline in granulosa cell proliferation, restriction of follicular growth and inhibition of ovulation. An outstanding feature in the ovary is the intense angiogenesis that occurs during the early luteal phase. VEGF inhibitors markedly suppressed this angiogenesis, resulting in a marked restriction in the development of the microvascular tree and suppression of plasma progesterone. These studies showed that VEGF is essential for normal follicular and luteal angiogenesis and function, and demonstrated how luteal angiogenesis in particular could serve as a sensitive bioassay for putative angiogenic antagonists. Antagonists of VEGF are potent tools for investigating the role of angiogenic factors within the ovary and may have applications to the treatment of reproductive disorders characterised by alterations in normal vascular structure or function. © Springer 2005.
引用
收藏
页码:101 / 116
页数:15
相关论文
共 76 条
  • [1] Folkman J., Angiogenesis in female reproductive organs, Steroid Hormones and Uterine Bleeding, pp. 143-158, (1992)
  • [2] Reynolds L.P., Killilea S.D., Redmer D.A., Angiogenesis in the female reproductive system, FASEB J, 6, pp. 886-892, (1992)
  • [3] Shweiki D., Itin A., Neufeld G., Et al., Patterns of vascular endothelial growth factor (VEGF) and VEGF receptors in mice suggest a role in hormonally regulated angiogenesis, J Clin Invest, 91, pp. 2235-2243, (1993)
  • [4] Wiegand S.J., Boland P., Yancopoulos D., Cooperative roles of the angiopoietins and vascular endothelial growth factor in ovarian angiogenesis, Ovulation Evolving Scientific and Clinical Concepts, pp. 175-186, (2000)
  • [5] Balakier H., Stronell R.D., Colour Doppler assessment of folliculogenesis in in vitro fertilization patients, Fertil Steril, 62, pp. 1211-1216, (1994)
  • [6] Campbell S., Bourne T.H., Waterstone J., Et al., Transvaginal colour blood flow imaging of the periovulatory follicle, Fertil Steril, 60, pp. 433-438, (1993)
  • [7] Wulff C., Wiegand S.J., Saunders P.T.K., Et al., Angiogenesis during follicular development in the primate and its inhibition by treatment with truncated Flt-1Fc (vascular endothelial growth factor trapA40), Endocrinology, 142, pp. 3244-3254, (2001)
  • [8] Fraser H.M., Lunn S.F., Non human primates in female reproductive medicine, Reproduction in Non-human Primates: A Model System for Human Reproductive Physiology and Toxicology, pp. 27-59, (1999)
  • [9] Fraser H.M., Groome N.P., McNeilly A.S., Follicle stimulating hormone-inhibin B interactions during the follicular phase of the primate menstrual cycle revealed by GnRH antagonist and anti-estrogen treatment, J Clin Endocrinol Metab, 84, pp. 1365-1369, (1999)
  • [10] Wulff C., Wilson H., Wiegand S.J., Et al., Prevention of thecal angiogenesis, antral follicular growth, and ovulation in the primate by treatment with vascular endothelial growth factor trap R1R2, Endocrinology, 143, pp. 2797-2807, (2002)